logo
Turbulence in the Oncology Workforce: A Silver Lining

Turbulence in the Oncology Workforce: A Silver Lining

Medscape6 hours ago

Physicians are in the midst of a tectonic shift in workforce patterns that could have ramifications lasting decades.
In a few short months, the current administration has implemented policies that will drastically reduce federal funding for academic science. These massive cuts include hundreds of terminated grants and slashed funding for 'indirect costs' for National Institutes of Health (NIH) research grant recipients. Alongside the federal budget cuts, entire divisions of the NIH and National Science Foundation are also being reorganized.
Clinicians at many academic institutions have been advised to prepare for uncertainty, while physicians and scientists have been instructed to restrict research hiring and spending, even terminate staff without existing grants or contracts. On top of that, entire global health programs have been decimated, and 'reduction in force' emails at the FDA, CDC, or Centers for Medicare and Medicaid Services have left many experts without a job.
However, amid this turbulence and confusion, there's a potential silver lining. The assaults on research funding and government programs may inadvertently help address a major issue: the physician shortage.
As many of my colleagues at academic institutions contemplate their next move, I suspect that oncologists may find themselves returning to full-time clinical practice and patient care.
And that may not be a bad thing.
Prior to the Trump administration's policies, the proportion of clinicians-hours spent seeing patients had declined nearly 8% over a decade. The number of doctors who spent most of their time seeing patients had dropped considerably as well. In fact, a 2024 survey from the American Medical Association found that over 35% of physicians expressed at least some interest in leaving clinical practice altogether. This, coupled with a massive influx of physicians entering retirement, is likely to exacerbate a growing physician shortage problem.
But what if more of us now choose to increase our time in the clinic or start practicing full time?
For many of my colleagues who cannot sustain a non-clinical career, I think that a return to full-time patient care will be a practical, even enticing move. And considering the shortages of physicians across almost all specialties, including oncology, doctors seeking refuge in clinical practice would be a welcome development.
Would I be content with a career that is increasingly more clinical? I think I would be. For me, clinical practice represents the ultimate refuge, the source of stability in a career that could otherwise be ruled by frequent career transitions encountered in the business world. The patient exam room is the one place where I can focus on a one-on-one relationship instead of the hustle and bustle of grant applications and administrative tasks.
Since patient care is often a health system's top revenue source, if more oncologists return to full-time practice, we may have more leverage to negotiate solutions that reduce burnout, advance practice providers, or provide greater vacation time. I also suspect that many clinicians who choose to spend more time with patients will do so as part of a medical group or private practice — potentially reversing a decades-long trend of doctors leaving private practice to work as employed physicians.
There are several tools that can help physicians make this transition easier. For one, the emergence of ambient artificial intelligence (AI) scribing may curb the exodus from clinical practice by reducing excessive documentation burdens. Instead of hyperbolic claims of AI 'replacing' physicians, I suspect that the AI revolution will simply provide physicians the necessary tools to be more efficient.
The growth of telemedicine and remote patient care platforms is another enabling factor. The rise of these virtual clinics means that physicians are no longer limited by geographically boundaries when practicing medicine. Continuing COVID-era policies that allow physicians to practice across state lines would also help.
If more physicians contemplate a return to their clinical roots, we have an opportunity to reshape the patient care experience in ways that both serve our communities and that create more sustainable clinical careers.
The physician workforce has always been adaptable. Now, if we can find our way back to the exam room, we will bring with us diverse experiences from research, policy, and business that can improve clinical practice.
Perhaps the silver lining in today's uncertainty is the chance to rediscover what drew us to medicine in the first place — the profound privilege of caring for patients — while leveraging our broader perspectives to address the systemic issues that drove many away in the first place. The future of healthcare may depend on our ability to transform this moment of professional disruption into one of renewal and recommitment to our core mission.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Exercise Scientist: This Simple Workout Plan Helps Maintain Muscle When You're Low on Time
Exercise Scientist: This Simple Workout Plan Helps Maintain Muscle When You're Low on Time

Yahoo

time26 minutes ago

  • Yahoo

Exercise Scientist: This Simple Workout Plan Helps Maintain Muscle When You're Low on Time

Exercise Scientist: This Simple Workout Plan Helps Maintain Muscle When You're Low on Time originally appeared on Men's Fitness. When you've worked hard for your gains, you don't want to lose them—especially if life has gotten busy, making it difficult to get to the gym. But it's possible to work out with a busy schedule. It may take less time than you might think, too. Exercise scientist Mike Israetel appeared as a guest on The Diary of a CEO Podcast, explaining that staying in good shape doesn't require hours in the gym each day—or even each week. His take: Two hours a week is all it takes to maintain your gains, maybe even improve them. "People think the amount of training it takes to get into great shape is exactly the same exact amount of training you have to continuously do to stay in good shape," Israetel that's a myth. He explained that most of the body's complex systems operate in a way where it takes significantly more effort to create change than it does to maintain progress. That means once you've built a solid fitness foundation, upkeep is far easier than people assume. "Two hours total per week week can at the very least maintain what you have, essentially indefinitely," he says. If you're in a busy season of life struggling to find time to train, don't worry about hitting the gym every day. Focus on consistent, efficient workouts—even short sessions count. It's even worth considering switching your workout split to three full-body workouts a week, hitting every essential movement pattern. "You can actually train a lot less and keep all of your gains and maybe make some more," Israetel says. Consistency beats volume when you're busy. And with just a couple hours a week, you can stay strong, fit, and Scientist: This Simple Workout Plan Helps Maintain Muscle When You're Low on Time first appeared on Men's Fitness on Jun 18, 2025 This story was originally reported by Men's Fitness on Jun 18, 2025, where it first appeared.

Key Highlights in Ovarian Cancer From ASCO 2025
Key Highlights in Ovarian Cancer From ASCO 2025

Medscape

time34 minutes ago

  • Medscape

Key Highlights in Ovarian Cancer From ASCO 2025

Novel drug combinations that improve outcomes, outstanding questions about treatment sequence, and encouraging results in chemotherapy resistant disease are among the ovarian cancer highlights presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Stephanie Gaillard, from Johns Hopkins School of Medicine, Baltimore, Maryland, begins with the ROSELLA trial of relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer. The results showed improved progression-free survival (PFS) and overall survival (OS) in this difficult-to-treat population. Next, she discusses the TRUST trial in advanced ovarian cancer, comparing radical upfront surgical therapy followed by chemotherapy with neoadjuvant chemotherapy followed by surgery, followed by further chemotherapy. Although PFS was improved by upfront surgery, OS was not, leaving the treatment sequence open to question. Dr Gaillard then reports on an updated survival analysis from the OVATION-2 study of intraperitoneal IMNN-001 plus neoadjuvant chemotherapy in newly diagnosed advanced epithelial ovarian cancer. The approach achieved impressive OS, alongside the previously reported PFS benefit. Finally, she reports on a phase 2 study of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma. The combination showed encouraging response rates and PFS in a population known to be highly resistant to chemotherapy.

His custom cancer therapy is in an NIH freezer. He may not get it in time.
His custom cancer therapy is in an NIH freezer. He may not get it in time.

Yahoo

time40 minutes ago

  • Yahoo

His custom cancer therapy is in an NIH freezer. He may not get it in time.

Richard Schlueter, 56, was planting cucumbers and squash in his community garden plot in Greensboro, Georgia, in May when he tore open a bag of soil and heard a pop. His collarbone had snapped. In early June, a scan revealed that the cancer that started in his tonsils was racing through his bones. That day, he called a medical team at the National Institutes of Health that had created an experimental cell therapy, custom-made to attack his cancer as part of a clinical trial. He needed it. Now. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Instead, he received more bad news: His therapy would be delayed at least a month because of staff cuts at NIH. A week later, Schlueter and his wife, Michelle, saw NIH Director Jay Bhattacharya push back on concerns raised by his own staff that the ouster of essential employees and other disruptions to the biomedical research agency were harming science and patients. Bhattacharya said on X that objections raised in a document called the Bethesda Declaration contained 'fundamental misconceptions' about NIH's new direction. Each termination was being reviewed, and some workers were reinstated, he added. But the Schlueters had a front-row seat to the effects of the job losses. Richard's therapy was in a freezer, nearly ready to go. All along, they had been told the final step of preparation takes three to four weeks. But on June 3, his NIH doctor informed him that it would now take eight to 10 weeks because of cuts to essential lab personnel - a painful illustration of the life-and-death stakes of the administration's approach to shrinking the government workforce. 'I'm petrified. I have to do something,' Richard said. 'My cancer is on the move.' The Washington Post first reported in early April that the production of specialized immune-cell therapies for metastatic cancer patients was delayed. Two highly skilled technicians who prepared cells for treatments were fired in the probationary purge in February, according to Steven Rosenberg, an NIH immunotherapy pioneer who leads multiple trials. He declined to say how many patients were affected, but his team now treats one patient per week, down from two or three before the cuts. 'There are some patients who might have to wait until September,' Rosenberg said. 'These are all patients with metastatic cancer that is progressive. You can imagine the difficulty as we have to tell them these things.' An official with the Department of Health and Human Services, which oversees NIH, said the agency had ways of addressing the delays. Rosenberg has been granted permission to hire contractors or to request help from other scientists from across NIH, said the official, who spoke on the condition of anonymity to criticize an employee. Rosenberg said he has been working urgently to try to rehire a scientist who was fired since he was given permission to do so last week, but the federal contracting process is slow and the scientist has been interviewing for other jobs. He noted that to prepare the cells for patients requires special training that takes four to six months. - - - National Institutes of Hope Richard's cancer nightmare started with what he thought was acid reflux. A few weeks after his annual physical in January 2024, he noticed a metallic taste in the back of his throat. Looking in the bathroom mirror, he saw little white pustules on one of his tonsils. A scan and biopsy showed it was head and neck squamous cell carcinoma, but an oncologist told him it was treatable, with an excellent chance of success. Unless it spread. On Richard's 55th birthday, March 11, 2024, he began chemotherapy and proton therapy. He had always taken good care of his health and was diligent with his treatments. But a scan in July revealed that the cancer had spread to his lungs and part of his chest cavity. 'It was heart-wrenching, and it was difficult,' said Richard, a founding partner of an Atlanta law firm. 'I'm a fact-finder, and I spend a lot of time researching and trying to find a path to remission or a potential cure. And it's a pretty bleak outlook.' Richard's efforts led him to NIH, where he felt blessed to qualify for a trial led by Rosenberg. Doctors would take a biopsy of his cancer and find and isolate immune cells called TIL, tumor-infiltrating lymphocytes. They would use lab tests to select the cells that recognized Richard's cancer and expand the population. Then, they would reinfuse them into his body. There are no guarantees with clinical research. Patients who qualify for the trial have exhausted standard treatments. But it gave the Schlueters something they had been missing: hope. 'Patients often refer to us not as the National Institutes of Health, but the National Institutes of Hope,' Rosenberg said. In January, Richard went to NIH for surgery to remove two tumors in his lungs and begin the process of isolating and testing the TIL cells. He read the NIH credo - to improve the human condition throughout the world - emblazoned on a wall of the Clinical Center and was so moved that he sent a photo of it to his three children. 'The staff, the physicians, the amount of empathy, care and mission that I've experienced over four visits to their research hospital has been just super gratifying,' Richard said. 'In many ways, I'm a guinea pig that may be helping other people. But I also have the byproduct that if it works, it will help me.' In late March, Richard returned to NIH, thinking it was go time. Instead a scan showed that the tumors in his lungs had unexpectedly become smaller. He returned home, knowing his therapy would be ready in the freezer if he took a turn for the worse. - - - No time to wait Rosenberg's team meets every Monday to discuss patient cases, and for months they have had to make difficult calls to seriously ill people. Richard is just one. Natalie Phelps, a mother of two from Bainbridge Island, Washington, with metastatic colorectal cancer, is waiting for cells in another of Rosenberg's trials. This one uses a different form of immunotherapy, but it is also slowed because of the loss of critical personnel. Last Friday, she gave The Post an update: 'So frustrating. I should be having treatment now, but instead I had to restart chemo and will be returning to start the treatment process' in late July. Two scientists on Rosenberg's team who have specialized skills to prepare cells for immunotherapy trials were among the thousands of probationary employees fired in the Trump administration's push to shrink the federal workforce. The one who would have finalized Richard's infusion had worked at NIH since 2020 and was recently hired as a full-time employee because she was considered so effective, according to Rosenberg. But that made her vulnerable, as a probationary employee with fewer protections. Rosenberg is trying to hire her back on contract using nongovernment funding. Richard is an optimist. His biggest fear is not qualifying for the experimental immune cells that he hopes could beat back his cancer. Doing nothing isn't an option because his cancer is spreading rapidly. Radiation might buy him time but leave his white blood cell count too low to be eligible for the trial. Robert L. Ferris, a head and neck surgical oncologist at the University of North Carolina Lineberger Comprehensive Cancer Center, said patients such as Richard have tough and tragic cases where standard medical care has been exhausted. Ferris is not involved in Richard's care, but the doctor said the trajectory of a cancer like this is grim. It is unlikely the cell therapy will cure Richard, Ferris cautioned, but science progresses through individual cases like his. And if Richard is forced to wait too long, he could be too frail to try it. 'If the cells are ready, you would want to give it to him now,' Ferris said. In mid-May, Richard was golfing with his nephew and his son. He was running, swimming, biking and lifting weights. The only sign something was awry was a red rash on his face that resembled a sunburn, a side effect of one of his treatments. But as the cancer has spread through his bones, his arms have become weak, and he has a suspected microfracture in his right arm. Pain in a hip makes it hard to get out of a chair. The Schlueters' 30th wedding anniversary celebration in early June was a joyous occasion, but Richard struggled to walk down the aisle to renew their vows. Even if the therapy doesn't save Richard, his family hopes his experience can help others. 'If he misses [it], not only is it is it devastating for his family, but it's devastating for all the patients behind him that could have learned something scientifically - on why it was successful or not successful,' Michelle said. 'He's like a test pilot.' Related Content Trump is as unpredictable as ever, even when faced with war Field notes from the end of life: My thoughts on living while dying He's dying. She's pregnant. His one last wish is to fight his cancer long enough to see his baby.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store